Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd...

Key Takeaway: Alkermes plc announced that its CEO, Richard Pops, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will include a corporate overview and will be followed by a question and answer session. Investors can access the live webcast through Alkermes' website.
Price reaction · baseline $28.62 (2024-01-02 close) · hit after-hours · 1 other ALKS headline(s) in the window, move may be shared
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes will present at a prestigious healthcare conference.
  • The CEO will provide a corporate overview and update.
  • The event includes a Q&A session for investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and update at the 42 nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST ( 2:15 p.m. EST / 7:15 p.m. GMT ), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland , Alkermes has a research and development center in Waltham , Massachusetts ; a research and manufacturing facility in Athlone , Ireland ; and a manufacturing facility in Wilmington, Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes present at the J.P. Morgan Conference?

Alkermes will present on January 10, 2024, at 11:15 a.m. PST.

Who will represent Alkermes at the conference?

CEO Richard Pops will provide the corporate overview.

How can investors access the presentation?

The live webcast will be available on Alkermes' website under the Investors tab.

Will there be a Q&A session?

Yes, a question and answer session will follow the presentation.

Last updated: Jan 3, 2024